Monoclonal antibodies to fibroblast growth factor receptor 2
AssigneeGalaxy Biotech, LLC
InventorsKyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Claims18
Synthetic genes encoding heavy and light chain variable regions of a humanized or human monoclonal antibody (mAb) which binds to FGFR2IIIb but not FGFR2IIIc and inhibits growth of a human tumor xenograft in a mouse.
2-4. (canceled)
6-7. (canceled)
Synthetic genes encoding a monoclonal antibody (mAb) that competes for binding to FGFR2 with an antibody selected from the group of GAL-FR21, GAL-FR22 and GAL-FR23.
13-15. (canceled)
Synthetic genes encoding heavy and light chain variable region of a humanized antibody comprising a humanized light chain comprising CDRs from the sequence in FIG. 13A (GAL-FR21) and a humanized heavy chain comprising CDRs from the sequence of FIG. 13B (GAL-FR21), or comprising a humanized light chain comprising CDRs from the sequence in FIG. 16A (GAL-FR22) and a humanized heavy chain comprising CDRs from the sequence of FIG. 16B (GAL-FR22).
Dependencies are inferred from the claim text.